<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacotherapy for hypertension in adults aged 18 to 59 years - Musini, VM - 2017 | Cochrane Library</title> <meta content="Pharmacotherapy for hypertension in adults aged 18 to 59 years - Musini, VM - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008276.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacotherapy for hypertension in adults aged 18 to 59 years - Musini, VM - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008276.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008276.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacotherapy for hypertension in adults aged 18 to 59 years" name="citation_title"/> <meta content="Vijaya M Musini" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="vijaya@ti.ubc.ca" name="citation_author_email"/> <meta content="Francois Gueyffier" name="citation_author"/> <meta content="Hopital Cardio‐Vasculaire et Pneumologique Louis Pradel" name="citation_author_institution"/> <meta content="Lorri Puil" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="Douglas M Salzwedel" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="James M Wright" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD008276.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/08/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008276.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008276.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008276.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antihypertensive Agents [adverse effects, *therapeutic use]; Bendroflumethiazide [therapeutic use]; Blood Pressure [drug effects]; Cause of Death; Coronary Disease [mortality, prevention &amp; control]; Hypertension [*drug therapy, mortality]; Methyldopa [therapeutic use]; Myocardial Infarction [mortality, prevention &amp; control]; Patient Dropouts [statistics &amp; numerical data]; Propranolol [therapeutic use]; Randomized Controlled Trials as Topic; Stroke [mortality, prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008276.pub2&amp;doi=10.1002/14651858.CD008276.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="PrHmaMrX";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008276\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008276\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008276\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008276\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","ru","ms","hr","fr","pt","fa","zh_HANT"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008276.pub2",title:"Pharmacotherapy for hypertension in adults aged 18 to 59 years",firstPublishedDate:"Aug 16, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hypertension Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008276.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008276.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008276.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008276.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008276.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008276.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008276.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008276.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008276.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008276.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7406 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008276.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/full#CD008276-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/full#CD008276-sec-0092"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/full#CD008276-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/full#CD008276-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/full#CD008276-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/full#CD008276-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/full#CD008276-sec-0067"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/full#CD008276-sec-0086"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/appendices#CD008276-sec-0097"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/table_n/CD008276StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/table_n/CD008276StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacotherapy for hypertension in adults aged 18 to 59 years</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/information#CD008276-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Vijaya M Musini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/information#CD008276-cr-0003">Francois Gueyffier</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/information#CD008276-cr-0004">Lorri Puil</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/information#CD008276-cr-0005">Douglas M Salzwedel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008276.pub2/information#CD008276-cr-0006">James M Wright</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/information/en#CD008276-sec-0100">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 August 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008276.pub2">https://doi.org/10.1002/14651858.CD008276.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008276-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008276-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008276-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008276-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008276-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008276-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008276-abs-0001" lang="en"> <section id="CD008276-sec-0001"> <h3 class="title" id="CD008276-sec-0001">Background</h3> <p>Hypertension is an important risk factor for adverse cardiovascular events including stroke, myocardial infarction, heart failure and renal failure. The main goal of treatment is to reduce these events. Systematic reviews have shown proven benefit of antihypertensive drug therapy in reducing cardiovascular morbidity and mortality but most of the evidence is in people 60 years of age and older. We wanted to know what the effects of therapy are in people 18 to 59 years of age. </p> </section> <section id="CD008276-sec-0002"> <h3 class="title" id="CD008276-sec-0002">Objectives</h3> <p>To quantify antihypertensive drug effects on all‐cause mortality in adults aged 18 to 59 years with mild to moderate primary hypertension. To quantify effects on cardiovascular mortality plus morbidity (including cerebrovascular and coronary heart disease mortality plus morbidity), withdrawal due adverse events and estimate magnitude of systolic blood pressure (SBP) and diastolic blood pressure (DBP) lowering at one year. </p> </section> <section id="CD008276-sec-0003"> <h3 class="title" id="CD008276-sec-0003">Search methods</h3> <p>The Cochrane Hypertension Information Specialist searched the following databases for randomized controlled trials up to January 2017: the Cochrane Hypertension Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (from 1946), Embase (from 1974), the World Health Organization International Clinical Trials Registry Platform, and ClinicalTrials.gov. We contacted authors of relevant papers regarding further published and unpublished work. </p> </section> <section id="CD008276-sec-0004"> <h3 class="title" id="CD008276-sec-0004">Selection criteria</h3> <p>Randomized trials of at least one year' duration comparing antihypertensive pharmacotherapy with a placebo or no treatment in adults aged 18 to 59 years with mild to moderate primary hypertension defined as SBP 140 mmHg or greater or DBP 90 mmHg or greater at baseline, or both. </p> </section> <section id="CD008276-sec-0005"> <h3 class="title" id="CD008276-sec-0005">Data collection and analysis</h3> <p>The outcomes assessed were all‐cause mortality, total cardiovascular (CVS) mortality plus morbidity, withdrawals due to adverse events, and decrease in SBP and DBP. For dichotomous outcomes, we used risk ratio (RR) with 95% confidence interval (CI) and a fixed‐effect model to combine outcomes across trials. For continuous outcomes, we used mean difference (MD) with 95% CI and a random‐effects model as there was significant heterogeneity. </p> </section> <section id="CD008276-sec-0006"> <h3 class="title" id="CD008276-sec-0006">Main results</h3> <p>The population in the seven included studies (17,327 participants) were predominantly healthy adults with mild to moderate primary hypertension. The Medical Research Council Trial of Mild Hypertension contributed 14,541 (84%) of total randomized participants, with mean age of 50 years and mean baseline blood pressure of 160/98 mmHg and a mean duration of follow‐up of five years. Treatments used in this study were bendrofluazide 10 mg daily or propranolol 80 mg to 240 mg daily with addition of methyldopa if required. The risk of bias in the studies was high or unclear for a number of domains and led us to downgrade the quality of evidence for all outcomes. </p> <p>Based on five studies, antihypertensive drug therapy as compared to placebo or untreated control may have little or no effect on all‐cause mortality (2.4% with control vs 2.3% with treatment; low quality evidence; RR 0.94, 95% CI 0.77 to 1.13). Based on 4 studies, the effects on coronary heart disease were uncertain due to low quality evidence (RR 0.99, 95% CI 0.82 to 1.19). Low quality evidence from six studies showed that drug therapy may reduce total cardiovascular mortality and morbidity from 4.1% to 3.2% over five years (RR 0.78, 95% CI 0.67 to 0.91) due to reduction in cerebrovascular mortality and morbidity (1.3% with control vs 0.6% with treatment; RR 0.46, 95% CI 0.34 to 0.64). Very low quality evidence from three studies showed that withdrawals due to adverse events were higher with drug therapy from 0.7% to 3.0% (RR 4.82, 95% CI 1.67 to 13.92). The effects on blood pressure varied between the studies and we are uncertain as to how much of a difference treatment makes on average. </p> </section> <section id="CD008276-sec-0007"> <h3 class="title" id="CD008276-sec-0007">Authors' conclusions</h3> <p>Antihypertensive drugs used to treat predominantly healthy adults aged 18 to 59 years with mild to moderate primary hypertension have a small absolute effect to reduce cardiovascular mortality and morbidity primarily due to reduction in cerebrovascular mortality and morbidity. All‐cause mortality and coronary heart disease were not reduced. There is lack of good evidence on withdrawal due to adverse events. Future trials in this age group should be at least 10 years in duration and should compare different first‐line drug classes and strategies. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008276-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008276-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD008276-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD008276-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008276-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008276-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008276-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008276-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008276-abs-0013">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008276-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008276-abs-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008276-abs-0016">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008276-abs-0005" lang="en"> <h3>Treatment for hypertension in adults aged 18 to 59 years</h3> <p><b>Review question</b> </p> <p>We wanted to study the benefits and harms of using blood pressure lowering (antihypertensive) medicines in adults aged 18 to 59 years with raised blood pressure (hypertension). </p> <p>We searched the available medical literature to find all the trials that had assessed this question. The data included in this review is up to date as of January 2017. </p> <p><b>Background</b> </p> <p>Hypertension increases the risk of stroke, heart attacks and heart failure; therefore, the main goal of treatment with antihypertensive medicines is to reduce this risk. There is substantial evidence mostly in people older than 60 years that antihypertensive therapy reduces these outcomes. </p> <p><b>Study characteristics</b> </p> <p>We found seven studies that randomly assigned 17,327 people aged 18 to 59 years with hypertension to either antihypertensive medicines or placebo (pretend treatment)/no treatment<b>.</b> The average duration of treatment was five years. Medicine classes studied in most people included medicines called thiazide diuretics or beta‐blockers. </p> <p><b>Key results</b> </p> <p>Treatment may have little or no effect on death from any cause compared with placebo or no treatment (2.4% with placebo/no treatment versus 2.3% with treatment; low quality evidence) and it may reduce the number of people experiencing heart disease or death from heart disease from 4.1% to 3.2% (low quality evidence). It may reduce stroke by a small amount from 1.3% to 0.6% (low quality evidence). We are not certain about the effects of treatment on the number of people who had blocked arteries (low quality evidence). Withdrawal due to side effects increased from 0.7% to 3.0% although the quality of evidence for this result was very low. The effects of treatment on blood pressure varied between the studies and we are uncertain as to how much of a difference treatment makes on average. </p> <p><b>Conclusions</b> </p> <p>Antihypertensive medicines for adults aged 18 to 59 years with raised blood pressure have a small beneficial effect to reduce stroke. However, death due to all‐causes and heart attack were not reduced and withdrawals due to side effects were increased. </p> <p><b>Quality of evidence</b> </p> <p>The overall evidence was graded as low or very low quality.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008276-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008276-sec-0092"></div> <h3 class="title" id="CD008276-sec-0093">Implications for practice</h3> <section id="CD008276-sec-0093"> <p>Antihypertensive drugs used to treat predominantly healthy adults aged 18 to 59 years with mild to moderate primary hypertension have a small absolute effect to reduce cardiovascular mortality and morbidity (0.9% over a five‐year period) primarily due to reduction in cerebrovascular mortality and morbidity (0.7%). All‐cause mortality and coronary heart disease were not reduced. There is lack of good evidence on withdrawal due to adverse events. </p> </section> <h3 class="title" id="CD008276-sec-0094">Implications for research</h3> <section id="CD008276-sec-0094"> <p>Long‐term randomized controlled trials of at least 10 years' duration are needed to investigate which first‐line drug is best in people in this age group as they will potentially be taking these drugs over a long duration. Future randomized controlled head to head studies should compare first‐line low‐dose thiazides versus other first‐line classes and measure all‐cause mortality, total serious adverse events and total cardiovascular serious adverse events. Long‐term high‐quality observational studies may also provide valuable additional information. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008276-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008276-sec-0036"></div> <div class="table" id="CD008276-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antihypertensive drug therapy compared to control for hypertension in adults aged 18 to 59 years</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antihypertensive drug therapy compared to control for hypertension in adults aged 18 to 59 years</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> antihypertensive drug therapy (mean duration: 5 years)<br/> <b>Comparison:</b> control (placebo or untreated) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antihypertensive drug therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000<br/> (19 to 28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.94<br/> (0.77 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,776<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low <sup>1,2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total cardiovascular mortality + morbidity</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000<br/> (27 to 37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.78<br/> (0.67 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,278<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low <sup>1,3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR 0.9%, NNTB = 112</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cerebrovascular mortality + morbidity</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/> (5 to 9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.46<br/> (0.34 to 0.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,278<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low <sup>1,3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR 0.7%, NNTB 143</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Coronary heart disease mortality + morbidity</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (21 to 31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99<br/> (0.82 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,241<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low <sup>1,3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000<br/> (11 to 93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.82<br/> (1.67 to 13.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1,223<br/> (3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low <sup>1,2,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARI 3.8%, NNTH 27</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Decrease in SBP</b><sup>5</sup> </p> <p>at end of 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean SBP was 0</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 14.98 lower (20.44 lower to 9.52 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,845<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low <sup>1,3,7</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Decrease in DBP</b><sup>6</sup> </p> <p>at end of 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean DBP was 0</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 7.62 lower (10.55 blower to 4.69 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,857<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low <sup>1,3,7</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ARI:</b> absolute risk increase; <b>ARR:</b> absolute risk reduction; <b>CI:</b> confidence interval; <b>DBP:</b> diastolic blood pressure; <b>MD:</b> mean difference; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat to for an additional harmful outcome; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SBP:</b> systolic blood pressure. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Several additional trials met the inclusion criteria but did not report data in the 18‐ to 59‐year‐old subgroup of participants (which are listed under <a href="./references#CD008276-sec-0107" title="">Characteristics of excluded studies</a> table). </p> <p><sup>2</sup>Imprecision due to wide confidence interval. </p> <p><sup>3</sup>High risk of bias due to lack of blinding of physician and participants as well as incomplete outcome data reporting in the MRC‐TMH trial. </p> <p><sup>4</sup>Only 3 out of 7 included trials reported this outcome. The data from <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a> for this subgroup were not available. High risk of attrition bias and unclear risk of reporting bias of the <a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a> study which contributes 100% weight to the effect size. </p> <p><sup>5</sup>The range of change in SBP in the control group ranged from increase by 1.5 mmHg to decrease from 9 to 14 mmHg. </p> <p><sup>6</sup>The range of decrease in DBP in the control group ranged from 0.6 mmHg to 7 mmHg. </p> <p><sup>7</sup>Significant heterogeneity (I<sup>2</sup> &gt; 95%). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008276-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008276-sec-0037"></div> <section id="CD008276-sec-0038"> <h3 class="title" id="CD008276-sec-0038">Description of the condition</h3> <p>Elevated blood pressure (BP), commonly called hypertension, is an important healthcare problem internationally. Hypertension has been defined as a systolic blood pressure (SBP) of at least 140 mmHg or a diastolic blood pressure (DBP) of at least 90 mmHg, or both. The worldwide prevalence of elevated BP is about 26% of the adult population, and the prevalence increases with age (<a href="./references#CD008276-bbs2-0081" title="KearneyPM , WheltonM , ReynoldsK , MuntnerP , WheltonPK , HeJ . Global burden of hypertension: analysis of worldwide data. Lancet2005;365:217‐23. ">Kearney 2005</a>). Elevated blood pressure is a major contributor to adverse cardiovascular events (cardiovascular disease; CVD) and has been estimated to contribute 4.5% to the global disease burden (<a href="./references#CD008276-bbs2-0106" title="World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization/International Society of Hypertension (ISH) statement on management of hypertension. Journal of Hypertension2003;21:1983‐92. ">WHO 2003</a>). People of younger age (less than 60 years) have a lower prevalence of hypertension than older people. </p> <p>The main goal of antihypertensive treatment is to reduce strokes, myocardial infarctions (MI) and heart failure. Several systematic reviews have shown benefit of antihypertensive drug therapy in reducing cardiovascular mortality and morbidity primarily in people over 60 years of age (<a href="./references#CD008276-bbs2-0068" title="CollinsR , PetoR , MacMahonS , HebertP , FiebachNH , EberleinKA , et al. Blood pressure, stroke, and coronary heart disease ‐ Part 2, short‐term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet1990;335:827‐38. ">Collins 1990</a>; <a href="./references#CD008276-bbs2-0101" title="ThijsL , FagardR , LijnenP , StaessenJ , VanHoofR , AmeryA . A meta‐analysis of outcome trials in elderly hypertensives. Journal of Hypertension1992;10:1103‐9. ">Thijs 1992</a>; <a href="./references#CD008276-bbs2-0095" title="PsatyBM ,  SmithNL ,  SiscovickDS ,  KoepsellTD ,  WeissNS ,  HeckbertSR ,  etal . Health outcomes associated with antihypertensive therapies used as first‐line agents. A systematic review and meta‐analysis. JAMA1997;277(9):739‐45. ">Psaty 1997</a>; <a href="./references#CD008276-bbs2-0074" title="GueyffierF , BulpittC , BoisselJP , SchronE , EkbomT , FagardR , et al. for the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta‐analysis of randomised controlled trials. Lancet1999;353:793‐6. ">Gueyffier 1999</a>; <a href="./references#CD008276-bbs2-0096" title="PsatyBM , LumleyT , FurbergCD , SchellenbaumG , PahorM , AldermanMH , et al. Health outcomes associated with various antihypertensive therapies used as first‐line agents: a network meta‐analysis. JAMA2003;289:2534‐44. ">Psaty 2003</a>; <a href="./references#CD008276-bbs2-0089" title="MusiniVM , TejaniAM , BassettK , WrightJM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000028.pub2] ">Musini 2009</a>; <a href="./references#CD008276-bbs2-0108" title="WrightJM , MusiniVM . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] ">Wright 2009</a>). </p> <p>Does benefit due to antihypertensive therapy differ in different age groups? There are various claims made in the literature regarding the benefits of antihypertensive therapy in different age groups. One meta‐analysis of 31 trials with 190,606 participants by the Blood Pressure Lowering Treatment Trialists' Collaboration concluded that reduction of BP produces benefits in younger (aged less than 65 years) and older (aged greater than 65 years) adults, with no strong evidence that protection against major vascular events afforded by different drug classes varies substantially with age (<a href="./references#CD008276-bbs2-0067" title="Blood Pressure Lowering Treatment Trialists' Collaboration, TurnbullF , NealB , NinomiyaT , AlgertC , ArimaH , BarziF , et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta‐analysis of randomised trials. BMJ2008;336(7653):1121‐3. ">BPLTTC 2008</a>). In contrast, the results from the Prospective Studies Collaboration meta‐analysis by analyzing individual data of one million adults from 61 prospective observational studies of BP and mortality showed that at ages 40 to 69 years, each difference of 20 mmHg usual SBP (approximately 10 mmHg usual DBP) was associated with more than a two‐fold difference in the stroke death rate, and with two‐fold differences in the death rates from ischaemic heart disease (IHD) and other vascular causes. The annual absolute estimated differences in risk are greater in old age (<a href="./references#CD008276-bbs2-0094" title="LewingtonS , ClarkeR , QizilbashN , PetoR , CollinsR . Age‐specific relevance of usual blood pressure to vascular mortality: a meta‐analysis of individual data for one million adults in 61 prospective studies. Lancet2002;360(9349):1903‐13. ">Prospective Studies Collaboration 2002</a>). </p> <p>Although reduction in BP is believed to result in reduction in clinically important outcomes such as stroke or MIs, it a poor surrogate outcome measure for all‐cause mortality and morbidity. Similar or greater reduction in BP by different classes of antihypertensive drugs may not necessarily result in similar or greater magnitude of reduction in clinically relevant outcomes (<a href="./references#CD008276-bbs2-0108" title="WrightJM , MusiniVM . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] ">Wright 2009</a>). </p> </section> <section id="CD008276-sec-0039"> <h3 class="title" id="CD008276-sec-0039">Description of the intervention</h3> <p>High BP should be managed first by changing life style (eating a healthy diet with less salt, exercising regularly, quitting smoking and maintaining a healthy weight). When these lifestyle changes are not sufficient, treatment with antihypertensive drugs is recommended. Several different classes of medications are available to reduce BP (thiazide diuretics, beta‐blockers, angiotensin‐converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), calcium channel blockers and alpha‐blockers) (<a href="./references#CD008276-bbs2-0090" title="National Institute for Health and Care Excellence. Treating high blood pressure with lifestyle changes, August 2011, updated November 2016. www.nice.org.uk/guidance/cg127/ifp/chapter/treating‐high‐blood‐pressure‐with‐lifestyle‐changes (accessed prior to 28 July 2017). ">NICE 2016</a>). </p> </section> <section id="CD008276-sec-0040"> <h3 class="title" id="CD008276-sec-0040">How the intervention might work</h3> <p>Different classes of antihypertensive drugs have different mechanisms of action. The mechanism of action by which thiazide diuretics lower BP in the long term is not fully understood. After chronic use, thiazides lower peripheral resistance. The mechanism of these effects is uncertain as it may involve effects on 'whole body,' renal autoregulation or direct vasodilator actions (<a href="./references#CD008276-bbs2-0077" title='HughesAD . How do thiazide and thiazide‐like diuretics lower blood pressure?". Journal of the Renin‐Angiotensin‐Aldosterone System2004;5(4):155‐60. '>Hughes 2004</a>; <a href="./references#CD008276-bbs2-0084" title="LongoDL , FauciAS , KasperDL , HauserSL , JamesonJ , LoscalzoJ . Harrison's Principals of Internal Medicine. Vol. 2, New York (NY): McGraw‐Hill, 2012. [ISBN 978‐0‐07‐174887‐2] ">Longo 2012</a>). Thiazides act on the kidney to inhibit reabsorption of sodium (Na<sup>+</sup>) and chloride (Cl<sup>‐</sup>) ions from the distal convoluted tubules in the kidneys by blocking the thiazide‐sensitive Na<sup>+</sup>‐Cl<sup>‐</sup> symporter (<a href="./references#CD008276-bbs2-0069" title="DuarteJD , Cooper‐DeHoffRM . Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide‐like diuretics. Expert Review of Cardiovascular Therapy2010;8(6):793‐802. ">Duarte 2010</a>). They also increase calcium reabsorption at the distal tubule and increase the reabsorption of calcium ions (Ca<sup>2+</sup>) by a mechanism involving the reabsorption of sodium and calcium in the proximal tubule in response to sodium depletion. </p> <p>Alpha‐blockers (α<sub>1</sub> adrenergic receptor blockers) inhibit the binding of norepinephrine (noradrenaline) to the α<sub>1</sub> receptors causing vasodilation. </p> <p>Beta‐blockers are competitive antagonists that block the receptor sites for epinephrine (adrenaline) and norepinephrine on adrenergic beta‐receptors. Some block activation of all types of beta‐adrenergic receptors (β<sub>1</sub>, β<sub>2</sub> and β<sub>3</sub>) and others are selective for one of the three types of beta receptors (<a href="./references#CD008276-bbs2-0070" title="FrishmanWH , Cheng‐LaiA , NawarskasJ . Current Cardiovascular Drugs. 4th Edition. Philadelphia, PA 19106: Springer Science &amp; Business Media, 2005. ">Frishman 2005</a>). </p> <p>Calcium channel blockers reduce BP through various mechanisms: by vasodilation, reduction in the force of contraction of the heart, by slowing the heart beat and by directly reducing aldosterone production. </p> <p>ACE inhibitors block the conversion of angiotensin I (AI) to angiotensin II (AII). They thereby lower arteriolar resistance and increase venous capacity. They decrease cardiac output, cardiac index, stroke work and volume, and lower resistance in blood vessels in the kidneys. As a result of negative feedback of conversion of AI to AII, renin and AI increase in concentration in the blood. Bradykinin increases because of less inactivation by ACE. </p> <p>ARBs block the activation of angiotensin II AT<sub>1</sub> receptors. Blockage of AT<sub>1</sub> receptors directly causes vasodilation, reduces secretion of vasopressin, and reduces production and secretion of aldosterone. </p> </section> <section id="CD008276-sec-0041"> <h3 class="title" id="CD008276-sec-0041">Why it is important to do this review</h3> <p>Clinical trials in adults with mild to moderate hypertension have included people over a wide age range from 18 to 104 years of age. There are two Cochrane Reviews evaluating the effectiveness of antihypertensive drug therapy in people with primary hypertension compared to placebo or no treatment: "First line drugs for hypertension" in adults aged 18 years or older (<a href="./references#CD008276-bbs2-0108" title="WrightJM , MusiniVM . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] ">Wright 2009</a>) and an updated review "Pharmacotherapy of hypertension in the elderly" (aged 60 years or older) with a subgroup meta‐analysis in very elderly people (aged 80 years or older) (<a href="./references#CD008276-bbs2-0089" title="MusiniVM , TejaniAM , BassettK , WrightJM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000028.pub2] ">Musini 2009</a>). </p> <p><a href="./references#CD008276-bbs2-0108" title="WrightJM , MusiniVM . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] ">Wright 2009</a> found that despite a similar magnitude of reduction in BP, a surrogate outcome measure, the clinical effectiveness in terms of all‐cause mortality and cardiovascular mortality and morbidity was different for different drug classes. First‐line low‐dose thiazides reduced all morbidity and mortality outcomes. First‐line ACE inhibitors and calcium channel blockers may have been similarly effective but the evidence was less robust. First‐line high‐dose thiazides and first‐line beta‐blockers were inferior for some outcomes to first‐line low‐dose thiazides. However, the review did not provide data on clinical effectiveness of antihypertensive drug therapy in different age groups. </p> <p><a href="./references#CD008276-bbs2-0089" title="MusiniVM , TejaniAM , BassettK , WrightJM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000028.pub2] ">Musini 2009</a> concluded that all‐cause mortality as well as cardiovascular mortality and morbidity were modestly reduced in elderly people (aged 60 years or older). However, the decrease in all‐cause mortality was limited to people 60 to 79 years of age. </p> <p>Therefore, it is important to know the relative and absolute magnitude of the effect of antihypertensive drugs in different age groups of people with primary hypertension. This systematic review aimed to find the relative and absolute magnitude of the reduction in all‐cause mortality as well as cardiovascular mortality and morbidity in adults aged 18 to 59 years with primary hypertension (mild to moderate systolic or diastolic hypertension). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008276-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008276-sec-0042"></div> <p>To quantify antihypertensive drug effects on all‐cause mortality in adults aged 18 to 59 years with mild to moderate primary hypertension. To quantify effects on cardiovascular mortality plus morbidity (including cerebrovascular and coronary heart disease mortality plus morbidity), withdrawal due adverse events and estimate magnitude of systolic and diastolic blood pressure lowering at one year. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008276-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008276-sec-0043"></div> <section id="CD008276-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008276-sec-0045"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCT) of at least one year' duration. Trials must have included a control group that either received a placebo or received no antihypertensive therapy. </p> <p>We excluded trials using non‐randomized allocation methods such as alternate allocation, week of presentation or retrospective controls. Trials that compared two specific antihypertensive first‐line therapies without a placebo or untreated control were also excluded. </p> </section> <section id="CD008276-sec-0046"> <h4 class="title">Types of participants</h4> <p>Trials included only people aged 18 to 59 years or separately report outcomes for people in this age group. To maximize data inclusion, if trials included at least 90% of participants in the specified age group (18 to 59 years) but did not report outcomes data separately for this specific age group, we included the overall data in all randomized participants provided in these trials. </p> <p>Participants must have had primary hypertension with a SBP of at least 140 mmHg or a DBP of at least 90 mmHg, or both at baseline. </p> </section> <section id="CD008276-sec-0047"> <h4 class="title">Types of interventions</h4> <p>Acceptable antihypertensive drug therapies included: diuretics, ACE inhibitors, ARBs, beta‐blockers, combined alpha‐ and beta‐blockers, calcium‐channel blockers, alpha‐blockers, central sympatholytics, direct vasodilators or peripheral adrenergic antagonists. Drugs could have been administered alone or in combination, and in fixed or stepped care regimens. The control group must have received a placebo or no anti‐hypertensive therapy. </p> </section> <section id="CD008276-sec-0048"> <h4 class="title">Types of outcome measures</h4> <section id="CD008276-sec-0049"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008276-list-0001"> <li> <p>All‐cause mortality (death from all causes).</p> </li> </ul> </p> </section> <section id="CD008276-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008276-list-0002"> <li> <p>Cardiovascular mortality plus morbidity (included fatal and non‐fatal stroke, fatal and non‐fatal MI, sudden death, hospitalization or death from congestive heart failure and other significant vascular deaths such as ruptured aneurysms). It did not include angina, transient ischaemic attacks, surgical or other procedures, or accelerated hypertension. </p> </li> <li> <p>Cerebrovascular mortality plus morbidity including fatal and non‐fatal stroke.</p> </li> <li> <p>Coronary heart disease mortality plus morbidity including fatal and non‐fatal MI, and sudden or rapid cardiac death. </p> </li> <li> <p>Withdrawal due to adverse events.</p> </li> <li> <p>Decrease in SBP and DBP.</p> </li> </ul> </p> <p>When the primary trial did not report on outcomes that fitted the above definitions, decisions were made based on maximizing the inclusion of the data as defined in each included study and maintaining concordance with how the data were classified in previous reviews (<a href="./references#CD008276-bbs2-0089" title="MusiniVM , TejaniAM , BassettK , WrightJM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000028.pub2] ">Musini 2009</a>; <a href="./references#CD008276-bbs2-0108" title="WrightJM , MusiniVM . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] ">Wright 2009</a>). </p> </section> </section> </section> <section id="CD008276-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008276-sec-0052"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Hypertension Information Specialist (DS) conducted systematic searches in the following databases for RCTs without language, publication year or publication status restrictions: </p> <p> <ul id="CD008276-list-0003"> <li> <p>the Cochrane Hypertension Specialised Register via the Cochrane Register of Studies (CRS‐Web) (searched 23 January 2017); </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies (CRS‐Web) (searched 23 January 2017); </p> </li> <li> <p>MEDLINE Ovid (from 1946 onwards), MEDLINE Ovid Epub Ahead of Print and MEDLINE Ovid In‐Process &amp; Other Non‐Indexed Citations (searched 23 January 2017); </p> </li> <li> <p>Embase Ovid (searched 23 January 2017);</p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) (searched 23 January 2017); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/trialsearch" target="_blank">www.who.int/trialsearch</a>) (searched 23 January 2017). </p> </li> </ul> </p> <p>The search strategy used in this review was identical to the Cochrane Review on "First line drugs for hypertension" (<a href="./references#CD008276-bbs2-0108" title="WrightJM , MusiniVM . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] ">Wright 2009</a>) and "Pharmacotherapy for hypertension in elderly patients" (<a href="./references#CD008276-bbs2-0089" title="MusiniVM , TejaniAM , BassettK , WrightJM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000028.pub2] ">Musini 2009</a>). The Cochrane Hypertension Information Specialist (DS) modelled subject strategies for databases on the search strategy designed for MEDLINE. Where appropriate, they were combined with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomized controlled (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Box 6.4.b; <a href="./references#CD008276-bbs2-0075" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). Search strategies for major databases are provided in <a href="./appendices#CD008276-sec-0098">Appendix 1</a>. Search was not done for regulatory documents from the Food and Drug Administration (FDA) or European Medicine Agency (EMA). </p> <p>There were no language restrictions.</p> </section> <section id="CD008276-sec-0053"> <h4 class="title">Searching other resources</h4> <p>We carefully checked the bibliographies of previously published meta‐analyses on the treatment of hypertension to help identify references to trials (<a href="./references#CD008276-bbs2-0068" title="CollinsR , PetoR , MacMahonS , HebertP , FiebachNH , EberleinKA , et al. Blood pressure, stroke, and coronary heart disease ‐ Part 2, short‐term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet1990;335:827‐38. ">Collins 1990</a>; <a href="./references#CD008276-bbs2-0101" title="ThijsL , FagardR , LijnenP , StaessenJ , VanHoofR , AmeryA . A meta‐analysis of outcome trials in elderly hypertensives. Journal of Hypertension1992;10:1103‐9. ">Thijs 1992</a>; <a href="./references#CD008276-bbs2-0085" title="MacMahonS , RogersA . The effects of blood pressure reduction in older patients: an overview of ﬁve randomized controlled trials in elderly hypertensives. Clinical and Experimental Hypertension1993;15(6):967‐78. ">MacMahon 1993</a>; <a href="./references#CD008276-bbs2-0078" title="InsuaJT , SacksHS , LauTS , LauJ , ReitmanD , PaganoD , et al. Drug treatment of hypertension in the elderly: a meta‐analysis. Annals of Internal Medicine1994;121:355‐62. ">Insua 1994</a>; <a href="./references#CD008276-bbs2-0087" title="MulrowCD , CornellJA , HerreraCR , KadriA , FarnettL , AguilarC . Hypertension in the elderly: Implications and generalizability of randomized trials. JAMA1994;272:1932‐8. [MEDLINE: 95082133] ">Mulrow 1994</a>; <a href="./references#CD008276-bbs2-0093" title="PearceKA , FurbergCD , RushingJ . Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life? A meta‐analysis of hypertension treatment trials. Archives of Family Medicine1995;4:943‐50. ">Pearce 1995</a>; <a href="./references#CD008276-bbs2-0073" title="GueyffierF , FromentA , GoutonM . New meta‐analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. Journal of Human Hypertension1996;10:1‐8. [MEDLINE: 96219361] ">Gueyffier 1996</a>; <a href="./references#CD008276-bbs2-0095" title="PsatyBM ,  SmithNL ,  SiscovickDS ,  KoepsellTD ,  WeissNS ,  HeckbertSR ,  etal . Health outcomes associated with antihypertensive therapies used as first‐line agents. A systematic review and meta‐analysis. JAMA1997;277(9):739‐45. ">Psaty 1997</a>; <a href="./references#CD008276-bbs2-0088" title="MulrowC , LauJ , CornellJ , BrandM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews1998, Issue 2. [DOI: 10.1002/14651858.CD000028] ">Mulrow 1998</a>; <a href="./references#CD008276-bbs2-0074" title="GueyffierF , BulpittC , BoisselJP , SchronE , EkbomT , FagardR , et al. for the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta‐analysis of randomised controlled trials. Lancet1999;353:793‐6. ">Gueyffier 1999</a>; <a href="./references#CD008276-bbs2-0097" title="QuanA , KerlikowskeK , GueyffierF , BoisselJP , INDANA investigators. Efficacy of treating hypertension in women. Journal of General Internal Medicine1999;14:718‐29. ">Quan 1999</a>; <a href="./references#CD008276-bbs2-0091" title="NikolausT , SommerN , BeckerC . Treatment of arterial hypertension with diuretics, beta‐ and calcium channel blockers in old patients. Zeitschrift fur Gerontologie und Geriatrie2000;33:427‐32. ">Nikolaus 2000</a>; <a href="./references#CD008276-bbs2-0096" title="PsatyBM , LumleyT , FurbergCD , SchellenbaumG , PahorM , AldermanMH , et al. Health outcomes associated with various antihypertensive therapies used as first‐line agents: a network meta‐analysis. JAMA2003;289:2534‐44. ">Psaty 2003</a>; <a href="./references#CD008276-bbs2-0104" title="TurnbullF , Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood‐pressure‐lowering regimens on major cardiovascular events: results of prospectively‐designed overviews of randomised trials. Lancet2003;362:1527‐35. ">Turnbull 2003</a>; <a href="./references#CD008276-bbs2-0080" title="KangS , WuFY , AnN , RenM . A systematic review and meta‐analysis of the efficacy and safety of a fixed low‐dose perindopril‐indapamide combination as first‐line treatment of hypertension. Clinical Therapeutics2004;26(2):257‐70. ">Kang 2004</a>; <a href="./references#CD008276-bbs2-0065" title="TurnbullF , NealB , AlbertC , ChalmersJ , ChapmanN , CutlerJ , et al. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure‐lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Archives of Internal Medicine2005;165(12):1410‐9. ">BBLTTC 2005</a>; <a href="./references#CD008276-bbs2-0067" title="Blood Pressure Lowering Treatment Trialists' Collaboration, TurnbullF , NealB , NinomiyaT , AlgertC , ArimaH , BarziF , et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta‐analysis of randomised trials. BMJ2008;336(7653):1121‐3. ">BPLTTC 2008</a>; <a href="./references#CD008276-bbs2-0083" title="LawMR , MorrisJK , WaldNJ . Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta‐analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ2009;338:b1665. ">Law 2009</a>; <a href="./references#CD008276-bbs2-0089" title="MusiniVM , TejaniAM , BassettK , WrightJM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000028.pub2] ">Musini 2009</a>; <a href="./references#CD008276-bbs2-0108" title="WrightJM , MusiniVM . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] ">Wright 2009</a>; <a href="./references#CD008276-bbs2-0102" title="ThomopoulosC , ParatiG , ZanchettiA . Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta‐analyses, and meta‐regression analyses of randomized trials. Journal of Hypertension2014;32(12):2285‐95. ">Thomopoulos 2014</a>; <a href="./references#CD008276-bbs2-0099" title="SundströmJ , ArimaH , JacksonR , TurnbullF , RahimiK , ChalmersJ , et al. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of blood pressure reduction in mild hypertension. A systematic review and meta‐analysis. Annals of Internal Medicine2015;162:184‐91. ">Sundström 2015</a>; <a href="./references#CD008276-bbs2-0109" title="ZanchettiA , ThomopoulosC , ParatiG . Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. Circulation Research2015;116(6):1058‐73. ">Zanchetti 2015</a>; <a href="./references#CD008276-bbs2-0092" title="ParsonsC , MuradMH , AndersenS , MookadamF , LabonteH . The effect of antihypertensive treatment on the incidence of stroke and cognitive decline in the elderly: a meta‐analysis. Future Cardiology2016;12(2):237‐48. ">Parsons 2016</a>; <a href="./references#CD008276-bbs2-0100" title="TanXY , HuJB . ACEIs/ARBs for the prevention of type 2 diabetes in patients with cardiovascular diseases: a systematic review and meta‐analysis. International Journal of Clinical and Experimental Medicine2016;9(5):7624‐37. ">Tan 2016</a>; <a href="./references#CD008276-bbs2-0103" title="ThomopoulosC , ParatiG , ZanchettiA . Effects of blood pressure‐lowering treatment. 6. Prevention of heart failure and new‐onset heart failure ‐ meta‐analyses of randomized trials. Journal of Hypertension2016;34(3):373‐84. ">Thomopoulos 2016</a>; <a href="./references#CD008276-bbs2-0082" title="KızılırmakP , UresinY , OzdemirO , KilickiranB , TokgözoğluL , ÖngenZ . Renin‐angiotensin‐aldosterone system blockers and cardiovascular outcomes: a meta‐analysis of randomized clinical trials [Renin‐anjiyotensin‐aldosteron sistemi blokerleri ve kardiyovasküler sonuçları: Randomize klinik çalışmaların meta‐analizi]. Turk Kardiyoloji Dernegi Arsivi2017;45(1):49‐66. ">Kızılırmak 2017</a>; <a href="./references#CD008276-bbs2-0107" title="WiysongeCS , BradleyH , MayosiBM , MaroneyR , MbewuA , OpieLH , et al. Beta‐blockers for hypertension. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD002003.pub2] ">Wiysonge 2017</a>). </p> <p>We contacted experts in the field to identify any other trials missed in our search. We checked reference lists of included studies and contacted relevant trialists for information about unpublished or ongoing studies. </p> </section> </section> <section id="CD008276-sec-0054"> <h3 class="title" id="CD008276-sec-0054">Data collection and analysis</h3> <section id="CD008276-sec-0055"> <h4 class="title">Selection of studies</h4> <p>One review author (VM or LP or DS) screened the titles and abstracts of citations from the search. Articles were rejected on initial screen if they were not reports of an RCT or there was no possibility that the trial could fit the requirements of this review. Of the articles selected for further review, at least two review authors (VM, LP or JMW) independently assessed whether they met the inclusion criteria. </p> </section> <section id="CD008276-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (VM and JMW) independently performed data abstraction, cross‐checked and compared whenever possible to data from previously published meta‐analyses. The data abstraction form included details of study design, randomization, blinding, duration of treatment, baseline characteristics, number of participants lost to follow‐up, outcomes, intervention, statistical analysis and reporting. Trial characteristics are detailed in the <a href="./references#CD008276-sec-0106" title="">Characteristics of included studies</a> table. One review author (FG) provided data in the 18‐ to 59‐year‐old subgroup from the INDANA (<a href="./references#CD008276-bbs2-0072" title="GueyffierF , BoutitieF , BoisselJP , CoopeJ , CutlerJ , EkbomT , et al. INDANA: a meta‐analysis on individual patient data in hypertension. Protocol and preliminary results. Therapie1995;50:353‐62. ">Gueyffier 1995</a>) database for the <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a> trial. </p> </section> <section id="CD008276-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (VM and JMW) independently assessed risk of bias of each included trial and resolved any disagreements by adjudication or discussion with a third review author (AT or LP or FG). Risk of bias assessment was done according to Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008276-bbs2-0076" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). We assessed seven domains: randomization and allocation concealment to assess selection bias; blinding of the participants and physicians to assess performance bias; blinding of outcome assessor to assess detection bias; incomplete outcome reporting to assess attrition bias; selective reporting of outcomes to assess selective reporting bias and other bias to assess whether the study was funded by a drug manufacturer (in which case it was assessed as high risk of bias). </p> <section id="CD008276-sec-0058"> <h5 class="title">'Summary of findings' table</h5> <p>We used GRADEpro software to present the 'Summary of findings' table (<a href="./references#CD008276-bbs2-0071" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editors. GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group, 2013. Available from guidelinedevelopment.org/handbook, Updated October 2013. ">GRADEpro</a>). We decided to include all clinically relevant primary and secondary outcomes such as all‐cause mortality, total cardiovascular mortality and morbidity, cerebrovascular mortality and morbidity, coronary heart disease mortality and morbidity, withdrawal due to adverse events and magnitude of reduction in SBP and DBP. </p> <p>The five factors considered in grading overall quality of evidence were: limitations in study design and implementation, indirectness of evidence, unexplained heterogeneity or inconsistency of results, imprecision in results and high probability of publication bias. This approach specifies four levels of quality: high, moderate, low and very low quality evidence. The highest quality rating is for randomized trial evidence. Quality rating is downgraded by one level for each factor, up to a maximum of three levels for all factors. If there are severe problems for any one factor (when assessing limitations in study design and implementation, in concealment of allocation, loss of blinding or attrition over 50% of participants during follow‐up), randomized trial evidence may fall by two levels due to that factor alone. </p> </section> </section> <section id="CD008276-sec-0059"> <h4 class="title">Measures of treatment effect</h4> <p>We used Review Manager 5 for data synthesis and analyses (<a href="./references#CD008276-bbs2-0098" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager. Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). Quantitative analyses of outcomes were based on intention‐to‐treat results. We used risk ratios (RR) with 95% confidence intervals (CI) to combine outcomes across trials. If there was a significant difference in any outcome measure, we presented an absolute risk reduction (ARR) and number needed to treat for an additional beneficial (NNTB) or harmful (NNTH) outcome in the 'Summary of findings' table. For continuous outcomes (SBP and DBP), we calculated the mean difference (MD) with 95% CI to combine outcomes across studies. </p> </section> <section id="CD008276-sec-0060"> <h4 class="title">Unit of analysis issues</h4> <p>For all outcomes measures reported, we used data from each trial at the end of the follow‐up period mentioned in each trial, which varied from two to 10 years. </p> </section> <section id="CD008276-sec-0061"> <h4 class="title">Dealing with missing data</h4> <p>When participants were lost to follow‐up, we used data as reported for participants who were followed until end of the study in the analyses. Refer to how data was accounted for and included in each study under assessment of attrition bias in the <a href="#CD008276-sec-0072">Risk of bias in included studies</a> section. </p> <p>For example, in the <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a> study, events such as non‐fatal stroke or MI terminated participation in the study and follow‐up of such participants to the end of the study was not done. In such instances, data available up to the time point during which participants were followed were included in the analyses. </p> </section> <section id="CD008276-sec-0062"> <h4 class="title">Assessment of heterogeneity</h4> <p>We tested heterogeneity of treatment effect between the trials using a standard Chi² statistic for heterogeneity. We used the fixed‐effect model to obtain summary statistics of pooled trials, unless there was significant between‐study heterogeneity, in which case we used the random‐effects model to test statistical significance. When heterogeneity was estimated to be significant (I² greater than 50%), we explored the factors contributing to heterogeneity. </p> </section> <section id="CD008276-sec-0063"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess publication bias if at least 10 studies met the inclusion criteria using a funnel plot. However, in this review, only seven studies met the inclusion criteria and provided data for quantitative analyses, so funnel plot analyses were not performed. </p> </section> <section id="CD008276-sec-0064"> <h4 class="title">Data synthesis</h4> <p>We used Review Manager 5 to perform data synthesis and analyses (<a href="./references#CD008276-bbs2-0098" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager. Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We presented dichotomous outcomes as RR with 95% CI using a fixed‐effect model and continuous outcomes (SBP and DBP) as MD with 95% CI. </p> </section> <section id="CD008276-sec-0065"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Since most participants included in this review were subgroups of participants from four of the seven trials in adults aged 18 years or older, further dividing participants into various other subgroup and analysing outcomes would lead to an increase in alpha error. Multiple comparisons within further subgroups would increase the chances of finding significant differences and therefore was not done. </p> <p>When heterogeneity was significant (I² greater than 50%), we attempted to identify trials that would contribute to heterogeneity and explore their population characteristics, baseline BP, blinded or open‐label study design, use of antihypertensive drugs as fixed dose or stepped up therapy or response to placebo that would possibly explain the reason for heterogeneity. As the decrease in SBP and DBP showed significant heterogeneity, we presented results as MD with 95% CI using a random‐effects model instead of a fixed‐effect model. </p> </section> <section id="CD008276-sec-0066"> <h4 class="title">Sensitivity analysis</h4> <p>To test for robustness of results, we conducted the following sensitivity analyses:</p> <p> <ul id="CD008276-list-0004"> <li> <p>placebo controlled trials versus untreated trials;</p> </li> <li> <p>double blind trials versus open‐label or single‐blind trials;</p> </li> <li> <p>trials using combined starting drugs as stepped up therapy versus fixed‐dose therapy.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008276-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008276-sec-0067"></div> <section id="CD008276-sec-0068"> <h3 class="title">Description of studies</h3> <section id="CD008276-sec-0069"> <h4 class="title">Results of the search</h4> <p>Since the search strategy used in this review was identical to the Cochrane Review "First line drugs for hypertension" (<a href="./references#CD008276-bbs2-0108" title="WrightJM , MusiniVM . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] ">Wright 2009</a>) and "Pharmacotherapy for hypertension in elderly patients" (<a href="./references#CD008276-bbs2-0089" title="MusiniVM , TejaniAM , BassettK , WrightJM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000028.pub2] ">Musini 2009</a>), we included search findings to 2008 from these reviews. The PRISMA diagram for search to 2008 is not shown. </p> <p>The <a href="./references#CD008276-bbs2-0108" title="WrightJM , MusiniVM . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] ">Wright 2009</a> review search from 1946 to 2008 resulted the identification of 6232 citations. Of these, 5985 articles were rejected on initial screen as they were not reports of an RCT or there was no possibility that the trial could fit the requirements of this review. A total of 247 citations were retrieved for detailed evaluation by two review authors (JMW and VM) of which 13 were review articles. Of the remaining 234 citations, 59 were excluded upon detailed reading as they did not meet minimum inclusion criteria. A total of 175 reports of 57 potentially first‐line trials were evaluated. Forty‐eight reports of 33 trials were excluded and were listed in the 'Characteristics of excluded studies' table in the <a href="./references#CD008276-bbs2-0108" title="WrightJM , MusiniVM . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] ">Wright 2009</a> review. Finally, 127 reports of 24 trials were included in the <a href="./references#CD008276-bbs2-0108" title="WrightJM , MusiniVM . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] ">Wright 2009</a> review. Not all trials included in the <a href="./references#CD008276-bbs2-0108" title="WrightJM , MusiniVM . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] ">Wright 2009</a> review pertained to the age group 18 to 59 years old therefore we excluded 17 of the 24 studies included in the <a href="./references#CD008276-bbs2-0108" title="WrightJM , MusiniVM . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] ">Wright 2009</a> review. These are listed in the <a href="./references#CD008276-sec-0107" title="">Characteristics of excluded studies</a> table. </p> <p>The search strategy from 2008 to January 2017 resulted in 11,855 citations after removing duplicates. We screened the titles and abstracts and excluded 11,500 citations. Articles were rejected on this initial screen if the article was not a report of a RCT or there was no possibility that the trial could fit the requirements of this review. At leat two review authors (LP, VM or JMW) assessed the remaining articles to determine if they met the inclusion criteria. Three hundred and fifty‐five full‐text articles were retrieved of which all 355 articles were excluded on detailed reading as they did not meet the minimum inclusion criteria (<a href="#CD008276-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD008276-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt='This is a partial study flow diagram and shows search findings from 2008 until 2017. The search done from 1946 to 2008 was identical to the "First line drugs for hypertension" review in which 24 trials met the inclusion criteria of which 17 had to be excluded and only seven studies provided data for quantitative synthesis in 18‐ to 59‐year‐old participants.' data-id="CD008276-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>This is a partial study flow diagram and shows search findings from 2008 until 2017. The search done from 1946 to 2008 was identical to the "First line drugs for hypertension" review in which 24 trials met the inclusion criteria of which 17 had to be excluded and only seven studies provided data for quantitative synthesis in 18‐ to 59‐year‐old participants. </p> </div> </div> </div> <p>A total of seven studies (in 27 reports) identified previously in the "First line drugs for hypertension" review (<a href="./references#CD008276-bbs2-0108" title="WrightJM , MusiniVM . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] ">Wright 2009</a>) met the inclusion criteria and provide information in 18‐ to 59‐year‐old participants and were therefore included in the quantitative analyses. </p> <p>Please note that 59 trials including 17 trials from the "First line drugs for hypertension" review (<a href="./references#CD008276-bbs2-0108" title="WrightJM , MusiniVM . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] ">Wright 2009</a>) resulting from literature search from 1946 until 2017 were excluded and reasons for exclusion were listed under the <a href="./references#CD008276-sec-0107" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD008276-sec-0070"> <h4 class="title">Included studies</h4> <p>Seven trials met the inclusion criteria (<a href="./references#CD008276-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐89. ">Carter 1970</a>; <a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a>; <a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a>; <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>). </p> <p>This review included 17,327 (88%) participants aged 18 to 59 years from a total of 19,684 randomized participants from the seven included studies in adults with hypertension. In the <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a> trial, we were able to include only the people aged 18 to 59 years. The MRC‐TMH study contributed 14,541 (84%) of the total randomized participants with a mean age of 50 years and mean baseline BP of 160/98 mmHg and a mean duration of follow‐up of five years. Treatment used in this study was bendrofluazide 10 mg daily or propranolol 80 mg to 240 mg daily and with methyldopa added if required. </p> <p>Refer to the <a href="./references#CD008276-sec-0106" title="">Characteristics of included studies</a> table and <a href="#CD008276-tbl-0002">Table 1</a> for details regarding baseline characteristics for all included participants. No data regarding baseline characteristics was available for the specific 18‐ to 59‐year‐old subgroup of participants in four trials (<a href="./references#CD008276-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐89. ">Carter 1970</a>; <a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a>; <a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>). Three trials included only 18‐ to 59‐year‐old participants (<a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>). <a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a> did not provide the age range of included participants. The mean age of participants included in these four trials was 41.3 years. </p> <div class="table" id="CD008276-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics of included studies in all randomized participants aged 18 years or older</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> <p><b> Study design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number of 18‐ to 59‐year‐old participants/total randomized participants (%)</b> </p> <p><b> Characteristics of all randomized participants in each study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mean baseline SBP/DBP </b> </p> <p><b> (mmHg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mean age (range)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Treatment used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcomes reported in 18‐ to 59‐year‐old participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008276-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐89. ">Carter 1970</a> </p> <p>Open label</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49/97 (50.5%);</p> <p>included all hypertensive survivors aged &lt; 80 years of ischaemic type major strokes admitted to Ashford Hospital. </p> <p>Men: 57%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165/101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>(40 to 79 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Untreated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stepped‐up therapy</p> <p>Bendrofluazide (93%), methyldopa and debrisoquine</p> <p>FU 4.0 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a> </p> <p>Double blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252/452 (55.7%).</p> <p>80% of participants had completed stroke in year before randomization; 16% completed stroke + TIA and 4% TIA only. Severe neurological disability in 9.9% of treated group and 5% of control group. </p> <p>Black: 80%</p> <p>Men: 60%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167/100</p> <p>77% of the drug treated and 74% of the placebo treated participants had SBP &lt; 180 mmHg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 years</p> <p>(&lt; 75 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐dose therapy</p> <p>Deserpidine 1 mg + methyclothiazide 10 mg</p> <p>FU 3.0 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality + morbidity</p> <p>Cerebrovascular mortality + morbidity</p> <p>CHD mortality + morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a> </p> <p>Single blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,541/17,354 (83.8%).</p> <p>Men: 52%.</p> <p>Primary prevention participants.</p> <p>Refer to exclusion criteria listed in <a href="./references#CD008276-sec-0106" title="">Characteristics of included studies</a> table. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161/98.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 years</p> <p>(35‐64 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> <p>288/12,375 (0.02%) participants randomly assigned to observation taking no tablets and merged with placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stepped‐up therapy</p> <p>Bendrofluazide 10 mg daily (71% monotherapy), propranolol 80‐240 mg daily (78% monotherapy), methyldopa added if required </p> <p>FU 4.9 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> <p>Cardiovascular mortality + morbidity</p> <p>Cerebrovascular mortality + morbidity</p> <p>CHD mortality + morbidity</p> <p>SBP</p> <p>DBP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a> </p> <p>Open label</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>785/785 (100%)</p> <p>Men: 100%</p> <p>Primary prevention participants.</p> <p>Refer to exclusion criteria listed in <a href="./references#CD008276-sec-0106" title="">Characteristics of included studies</a> table </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156/97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 years</p> <p>(40‐49 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Untreated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stepped‐up therapy</p> <p>Hydrochlorothiazide (95%), methyldopa and propranolol (26%).</p> <p>At 5‐year follow‐up, 36.7% were on hydrochlorothiazide alone, 26% were on hydrochlorothiazide + propranolol, 20% were on hydrochlorothiazide + methyldopa and 18% participants were on other drugs. </p> <p>FU 5.5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> <p>Cardiovascular mortality + morbidity</p> <p>Cerebrovascular mortality + morbidity</p> <p>CHD mortality + morbidity</p> <p>SBP</p> <p>DBP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a> </p> <p>Double blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>389/389 (100%)</p> <p>Men: 80%</p> <p>Primary prevention participants.</p> <p>Refer to exclusion criteria listed in <a href="./references#CD008276-sec-0106" title="">Characteristics of included studies</a> table </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147/99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 years</p> <p>(21‐55 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐dose therapy</p> <p>Chlorothiazide 500 mg twice daily + Rauwolfia serpentina 100 mg twice daily</p> <p>FU 7.0 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> <p>Cardiovascular mortality + morbidity</p> <p>Cerebrovascular mortality + morbidity</p> <p>CHD mortality + morbidity</p> <p>SBP</p> <p>DBP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a> </p> <p>Double blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299/380 (78.7%)</p> <p>Men: 100%</p> <p>Primary prevention participants.</p> <p>Refer to exclusion criteria listed in <a href="./references#CD008276-sec-0106" title="">Characteristics of included studies</a> table </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176/103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 years</p> <p>(range not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stepped‐up therapy</p> <p>First line: hydrochlorothiazide 100 mg + reserpine 0.2 mg</p> <p>Second line: hydralazine 75‐150 mg</p> <p>FU 3.3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality + morbidity</p> <p>Cerebrovascular mortality + morbidity</p> <p>CHD mortality + morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a> </p> <p>Double blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1012/1012 (100%)</p> <p>Men: 100%</p> <p>Primary prevention participants.</p> <p>Refer to exclusion criteria listed in <a href="./references#CD008276-sec-0106" title="">Characteristics of included studies</a> table </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SBP not reported/93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 years</p> <p>(range 21‐50 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stepped‐up therapy</p> <p>Chlorthalidone 50 mg, 100 mg (53% chlorthalidone alone)</p> <p>Reserpine 0.25 mg</p> <p>FU 1.5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> <p>Cardiovascular mortality + morbidity</p> <p>Cerebrovascular mortality + morbidity</p> <p>CHD mortality + morbidity</p> <p>DBP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total of 7 studies published from 1970 to 1986</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17,327/19,684 (88% of total randomized participants in the 7 studies were 18‐59 years of age) of which only 301/1,7327 (0.02%) participants were secondary prevention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP 147‐176/DBP 99‐103 mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean age 37.5‐45 years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5 RCTs were placebo controlled and 2 RCTS had untreated group as control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mostly high‐dose thiazide and beta‐blockers</b> </p> <p><b>Mean follow‐up 1.5‐7 years.</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5/7 RCTs report on all clinically important outcomes</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CHD: coronary heart disease; DBP: diastolic blood pressure; FU: follow‐up; SBP: systolic blood pressure; TIA: transient ischaemic attack. </p> </div> </div> <p>All seven trials used first‐line high‐dose thiazide drugs for lowering BP. Two trials evaluated beta‐blockers versus placebo (<a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>). Three of the seven trials used methyldopa (<a href="./references#CD008276-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐89. ">Carter 1970</a>; <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>). Two trials used reserpine (<a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a>; <a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a>). Five trials used a stepped approach to antihypertensive drug administration (<a href="./references#CD008276-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐89. ">Carter 1970</a>; <a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a>; <a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a>; <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>). The remaining two trials used a standard fixed dose of drug in the intervention arm. </p> <p>Two trials included only men (Oslo 1986; <a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>). Three trials did not report ethnicity (<a href="./references#CD008276-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐89. ">Carter 1970</a>; <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>). The four remaining trials reported ethnicity for all included participants. African‐Americans comprised the following percentages in these trials: <a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a> 80%; <a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a> 42%; <a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a> 25%; and <a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a> 28%. Three trials based entry on DBP (<a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a>; <a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a>). Four trials based entry on either SBP or DBP (<a href="./references#CD008276-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐89. ">Carter 1970</a>; <a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>). </p> <p>Definition of stroke differed across trials. In more recent trials, it was defined as the presence of neurological deficit lasting more than 24 hours. Older trials (such as <a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>) defined stroke as a neurological deficit lasting more than 24 hours or a marked increase in transient ischaemic attacks (twice the weekly prerandomization level of occurrence, more than four per week or deterioration of more than 8 points in neurological score). <a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a> defined stroke as typical weakness or paralysis. Some trials did not define stroke. In our opinion combining all strokes (including reversible ischaemic neurological deficit (RIND)), into one outcome is not optimal. More clinically relevant interpretations could be made if strokes were subdivided into three groups: strokes with no disability, strokes with mild disability and strokes with severe disability. The definition of MI and sudden death was consistent across most trials. MI was defined as typical chest pain with ECG changes or increased cardiac enzymes; sudden death was defined as death within 24 hours of first evidence of acute CVD or unrelated to other known pre‐existing diseases. </p> <p>It was possible in most trials to determine which participants were treated for primary or secondary prevention. All trials excluded people with angina and congestive heart failure, as these conditions would require use of antihypertensive drugs for reasons independent of their antihypertensive action. Some trials allowed people with prior MI or stroke if they were not recent (e.g. within the previous three months). Thus, by determining the baseline prevalence of stroke and MI it was possible to calculate the percentage that represented secondary prevention. In six trials, the study population consisted of predominantly ambulatory participants recruited from the community, primary care centres or hospital‐based clinics (<a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a>; <a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a>; <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>). Two trials were secondary prevention and included stroke survivors who were ambulatory and contributed 301 (0.02%) of total randomized participants<b>(</b><a href="./references#CD008276-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐89. ">Carter 1970</a>; <a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>). One trial did not report prevalence of stroke or MI (<a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a>). Three trials were 100% primary prevention (<a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>). </p> <p>One trial reported baseline prevalence of diabetes as 0% (<a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>). Three trials reported baseline prevalence of smoking (<a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a> 46.7%; <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a> 29.7%; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a> 41.7%;). </p> <p>Mean baseline BP for all the trials ranged from 147 mmHg to 176 mmHg for SBP and from 99 mmHg to 103 mmHg for DBP. One trial did not report baseline SBP level (<a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a>). For complete description of the BP inclusion criteria for each study see the <a href="./references#CD008276-sec-0106" title="">Characteristics of included studies</a> table. One trial that contributed the most weight to effect size in this review included mostly people receiving primary prevention followed up for a mean duration of five years with mean baseline BP of 160/98 mmHg (<a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>). The mean duration of follow‐up across the seven included studies ranged from two to 10 years. </p> </section> <section id="CD008276-sec-0071"> <h4 class="title">Excluded studies</h4> <p>Fifty‐nine trials resulting from the search from 1946 to 2017 were excluded from this review and reasons for exclusion are provided in the <a href="./references#CD008276-sec-0107" title="">Characteristics of excluded studies</a> table. Twenty‐four trials met the inclusion criteria in the "First line drugs for hypertension" review by <a href="./references#CD008276-bbs2-0108" title="WrightJM , MusiniVM . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] ">Wright 2009</a> and "Pharmacotherapy for hypertension in the elderly review" by <a href="./references#CD008276-bbs2-0089" title="MusiniVM , TejaniAM , BassettK , WrightJM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000028.pub2] ">Musini 2009</a>, but 17 were excluded from this review. The reasons for excluding them were mostly because they did not report outcomes separately for the 18 to 59 years age group or were conducted in people 60 years or older. </p> </section> </section> <section id="CD008276-sec-0072"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed risk of bias for each included study using the Cochrane 'Risk of bias' tool for RCTs as described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008276-bbs2-0076" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). Potential parameters of methodological quality listed in the 'Risk of bias' table include: method used to randomize participants, whether randomization was completed in an appropriate and blinded manner; whether participants, providers, outcome assessors, or a combination of these were blinded to assigned therapy; whether the control group received a placebo or no treatment; percent of participants who did not complete follow‐up (dropouts); percent of participants not on assigned active or placebo therapy at study completion; selective reporting of outcomes and other bias in terms of funding of the trial by the manufacturer. </p> <p>Refer to <a href="#CD008276-fig-0002">Figure 2</a> for the 'Risk of bias' graph which provides review authors' judgements about each risk of bias item presented as percentages across all included studies. Refer to <a href="#CD008276-fig-0003">Figure 3</a> for the 'Risk of bias' summary which provides review authors' judgements about each risk of bias item for each included study. </p> <div class="figure" id="CD008276-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008276-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008276-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008276-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008276-sec-0073"> <h4 class="title">Allocation</h4> <p>Randomization was at low risk of bias in six trials (<a href="./references#CD008276-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐89. ">Carter 1970</a>; <a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a>; <a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>). It was judged as unclear in <a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a>. </p> <p>Allocation concealment was at low risk of bias in six trials (<a href="./references#CD008276-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐89. ">Carter 1970</a>; <a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a>; <a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>), and unclear in <a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a>. </p> </section> <section id="CD008276-sec-0074"> <h4 class="title">Blinding</h4> <p>Blinding of participant and personnel was at low risk of bias in four trials (<a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a>; <a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a>). It was at high risk of bias in three trials; two as treating physicians were aware of the treatment being prescribed (<a href="./references#CD008276-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐89. ">Carter 1970</a>; <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>), and one as both participants and treating physicians were aware of the treatment being prescribed (<a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>). </p> <p>Blinding of outcome assessors was at low risk of bias in four trials (<a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a>; <a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>). It was at unclear risk of bias in two trials (<a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a>), and at high risk of bias in one trial as study did not mention blinding of physician or outcome assessor (<a href="./references#CD008276-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐89. ">Carter 1970</a>). </p> </section> <section id="CD008276-sec-0075"> <h4 class="title">Incomplete outcome data</h4> <p>Incomplete outcome data was at low risk of bias in two trials (<a href="./references#CD008276-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐89. ">Carter 1970</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>), at unclear risk of bias in three trials (<a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a>; <a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a>), and at high risk of bias in two trials (<a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>). In the <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a> trial, participant participation was terminated in the event of non‐fatal stroke or MI. In the <a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a> trial, attrition rate was high due to dropouts or occurrence of morbid events. Vital statistics information was unknown in 26 participants who dropped out. </p> </section> <section id="CD008276-sec-0076"> <h4 class="title">Selective reporting</h4> <p>Selective reporting was at low risk of bias in four trials (<a href="./references#CD008276-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐89. ">Carter 1970</a>; <a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>), and at unclear risk of bias in three trials (<a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a>; <a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a>). </p> </section> <section id="CD008276-sec-0077"> <h4 class="title">Other potential sources of bias</h4> <p>Other potential bias in terms of funding by the manufacturer was at low risk of bias in three trials (<a href="./references#CD008276-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐89. ">Carter 1970</a>; <a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a>), and at unclear risk of bias in four trials (<a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a>; <a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>). </p> </section> </section> <section id="CD008276-sec-0078"> <h3 class="title" id="CD008276-sec-0078">Effects of interventions</h3> <p>See: <a href="./full#CD008276-tbl-0001"><b>Summary of findings for the main comparison</b> Antihypertensive drug therapy compared to control for hypertension in adults aged 18 to 59 years</a> </p> <p>See <a href="./full#CD008276-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD008276-sec-0079"> <h4 class="title">All‐cause mortality</h4> <p>Antihypertensive drug therapy as compared to placebo or untreated control had no effect on all‐cause mortality (RR 0.94, 95% CI 0.77 to 1.13; participants = 16,776; studies = 5; I² = 43% <a href="./references#CD008276-fig-0004" title="">Analysis 1.1</a>). </p> <p>Data from two studies (<a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a>; <a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>) were not provided in the original <a href="./references#CD008276-bbs2-0088" title="MulrowC , LauJ , CornellJ , BrandM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews1998, Issue 2. [DOI: 10.1002/14651858.CD000028] ">Mulrow 1998</a> review for the 18‐ to 59‐year‐old subgroup. These two studies contributed 551 (3.2%) of total randomized participants included. </p> </section> <section id="CD008276-sec-0080"> <h4 class="title">Cardiovascular mortality plus morbidity</h4> <p>Antihypertensive drug therapy as compared to placebo or untreated control reduced cardiovascular mortality plus morbidity (RR 0.78, 95% CI 0.67 to 0.91; participants = 17,278; studies = 6; I² = 13%; <a href="./references#CD008276-fig-0005" title="">Analysis 1.2</a>). </p> <p>The original <a href="./references#CD008276-bbs2-0088" title="MulrowC , LauJ , CornellJ , BrandM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews1998, Issue 2. [DOI: 10.1002/14651858.CD000028] ">Mulrow 1998</a> review and the <a href="./references#CD008276-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐89. ">Carter 1970</a> study did not provide total cardiovascular mortality plus morbidity data in 29 (0.2%) of total randomized participants. </p> </section> <section id="CD008276-sec-0081"> <h4 class="title">Cerebrovascular mortality plus morbidity</h4> <p>Antihypertensive drug therapy as compared to placebo or untreated control reduced stroke (RR 0.46, 95% CI 0.34 to 0.64; participants = 17,278; studies = 6; I² = 40%; <a href="./references#CD008276-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD008276-sec-0082"> <h4 class="title">Coronary heart disease mortality plus morbidity</h4> <p>Antihypertensive drug therapy as compared to placebo or untreated control did not reduce coronary heart disease (RR 0.99, 95% CI 0.82 to 1.19; participants = 16,241; studies = 4; I² = 0%; <a href="./references#CD008276-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD008276-sec-0083"> <h4 class="title">Withdrawal due to adverse events</h4> <p>Data for withdrawal due to adverse events in the 18‐ to 59‐year‐old subgroup were not available in four trials (<a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a>; <a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a>; <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>). Three trials report this outcome (<a href="./references#CD008276-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐89. ">Carter 1970</a>; <a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>). However, two trials reported no adverse events in either the treatment and the control groups (<a href="./references#CD008276-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐89. ">Carter 1970</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>). The RR was based on one study (RR 4.82, 95% CI 1.67 to 13.92; participants = 1223; study = 1; <a href="./references#CD008276-fig-0008" title="">Analysis 1.5</a>) (<a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>). </p> <p>Withdrawal due to adverse events was not available in the 18‐ to 59‐year‐old subgroup in one trial (<a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>). </p> </section> <section id="CD008276-sec-0084"> <h4 class="title">Decrease in systolic and diastolic blood pressure</h4> <p>Four trials reported data for DBP in 18‐ to 59‐year‐old subgroup of participants at end of 1 year (<a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a>; <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>), and three studies reported data for SBP (<a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>). Therefore, we added this outcome to the list of secondary outcomes in the review. </p> <p>Antihypertensive drug therapy significantly lowered both SBP and DBP as compared to the control group. Since heterogeneity was significant for BP data results were presented using a random‐effects model (SBP: MD ‐14.98, 95% CI ‐20.44 to ‐9.52; participants = 14,845; studies = 3; I² = 95%; <a href="./references#CD008276-fig-0009" title="">Analysis 1.6</a>; DBP: MD ‐7.62, 95% CI ‐10.55 to ‐4.69; participants = 15,857; studies = 4; I² = 96%; <a href="./references#CD008276-fig-0010" title="">Analysis 1.7</a>). </p> </section> <section id="CD008276-sec-0085"> <h4 class="title">Sensitivity analysis</h4> <p>In a sensitivity analyses to test the robustness of the overall treatment effect size, we deselected trials based on placebo controlled versus untreated group; double‐blind versus open‐label or single‐blind trials; trials using combined starting drugs as stepped up therapy versus fixed dose therapy; and secondary prevention versus mostly primary prevention. In all these instances, there were no clinically important changes in the treatment effect. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008276-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008276-sec-0086"></div> <section id="CD008276-sec-0087"> <h3 class="title" id="CD008276-sec-0087">Summary of main results</h3> <p>This review summarizes the effects of antihypertensive drug therapy for elevated BP in adults aged 18 to 59 years. The pooled data showed that using antihypertensive drug therapy (mostly high‐dose thiazide diuretics) reduced cardiovascular mortality and morbidity primarily due to a reduction in cerebrovascular mortality and morbidity, but had no effect on all‐cause mortality or coronary heart disease. Withdrawals due to adverse events were increased with drug therapy. The mean decrease in SBP/DBP at end of 1 year was 15/8 mmHg. </p> </section> <section id="CD008276-sec-0088"> <h3 class="title" id="CD008276-sec-0088">Overall completeness and applicability of evidence</h3> <p>The subgroup of people 18 to 59 years of age from the <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a> study represented 84% of total randomized participants and thus contributed the most to the treatment effect size for all mortality and morbidity outcomes. Therefore, the evidence from this review is most applicable to people who were eligible for this study. The mean age of participants was 50 years and the mean baseline BP was 160/98 mmHg. This means that about half of the participants would be in the mild hypertension range and half would be in the moderate hypertension range. Most of the participants (97.8%) were being treated for primary prevention. The mean duration of follow‐up was five years. Treatment used in this study was first‐line bendrofluazide 10 mg daily or first‐line propranolol 80 mg to 240 mg daily and methyldopa was added if required. </p> <p>In this review, in five trials, about 40% of the participants did not achieve the DBP goal of less than 90 mmHg although three trials used stepped care therapy (<a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a>; <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>; <a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a>), and two trials used fixed‐dose combination therapy (<a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>). This observation is important to note because it implies that in routine practice a substantial proportion of people with elevated BP are unlikely to be able to achieve BP targets. This does not mean these people will not benefit as BP reduction is only partly responsible for the risk reduction of antihypertensive treatment (<a href="./references#CD008276-bbs2-0066" title="BoisselJP , GueyffierF , BoutitieF , PocockS , FagardR . Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments. Fundamental &amp; Clinical Pharmacology2005;19:579‐84. ">Boissel 2005</a>). </p> <p>The data on withdrawals due to adverse events was incomplete as only three out of seven trials reported this outcome, with two trials (total participants = 834) reporting zero events in both arms. <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a> was not included in the withdrawals due to adverse events outcome as that outcome was not available separately for the 18‐ to 59‐year age group. However, withdrawals due to adverse events were increased by drug treatment in the full <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a> trial (RR 4.81, 95% CI 4.15 to 5.58; absolute risk increase 8.9%). This is very similar to the estimate from the present review (RR 4.82; absolute risk increase 3.8%), which primarily represents the results of the <a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a> trial (participants = 389). Even though we have graded this outcome as very low quality evidence, it is likely a reasonably robust estimate. </p> <p>The thiazide arm of the <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a> trial was classified as high‐dose thiazide in the "First line drugs for hypertension" review (<a href="./references#CD008276-bbs2-0108" title="WrightJM , MusiniVM . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] ">Wright 2009</a>). That review concluded that using low‐dose thiazide was beneficial in terms of reducing all‐cause mortality, total cardiovascular events, coronary heart disease and stroke. This benefit for coronary heart disease and all‐cause mortality was not observed in first‐line high‐dose thiazide trials. Thus, first‐line low‐dose thiazides are preferred, even though we do not have any evidence for low‐dose thiazides in the age group studied here. </p> <p>We calculated the absolute risk reduction (ARR) and NNTB for clinical outcomes that were significantly reduced with antihypertensive therapy compared to placebo or untreated control groups. For cardiovascular mortality plus morbidity, the relative risk reduction was 22%, ARR was 0.9% and NNTB was 112. For cerebrovascular events (fatal and non‐fatal stroke) the relative risk reduction was 64%, ARR was 0.7%, and NNTB was 143. This means that approximately 112 people need to be treated for about five years to prevent one adverse cardiovascular event and most of this benefit comes from a reduction in stroke (cerebrovascular mortality and morbidity). </p> <p>Sensitivity analyses did not show any clinically important changes in the treatment effect. </p> <p><a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a> also contributed more than 90% of the weight to the estimate of BP reduction in this review. Therefore, the mean BP reduction found in this review was close to that seen in the <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a> trial. The BP lowering effect was greater in the other trials, which resulted in high heterogeneity. This is likely because the design and number of drugs used in the trials differed. </p> </section> <section id="CD008276-sec-0089"> <h3 class="title" id="CD008276-sec-0089">Quality of the evidence</h3> <p>The overall quality of the evidence was graded using online GRADEpro software (<a href="./references#CD008276-bbs2-0071" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editors. GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group, 2013. Available from guidelinedevelopment.org/handbook, Updated October 2013. ">GRADEpro</a>). The 'Summary of findings' table provided the grading of the quality of evidence for each clinically important outcome. All‐cause mortality, cardiovascular mortality plus morbidity, cerebrovascular mortality plus morbidity and coronary heart disease mortality plus morbidity were downgraded to low quality evidence because of high risk of performance and attrition bias as well as lack of reporting of data from several trials that had to be excluded (<a href="./full#CD008276-tbl-0001">summary of findings Table for the main comparison</a>). Low quality evidence means our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect. </p> <p>Withdrawal due to adverse events was downgraded to very low quality evidence as it was only reported in three of the seven trials meeting the inclusion criteria. Very low quality evidence means we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p>Since one study with high risk of performance and attrition bias provided most of the data to the estimated effect size, it is likely to be an overestimate of the true effect (<a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a>). </p> </section> <section id="CD008276-sec-0090"> <h3 class="title" id="CD008276-sec-0090">Potential biases in the review process</h3> <p>Reporting bias is possible as eight studies ( met the inclusion criteria but did not report data in the 18‐ to 59‐year‐old subgroup of participants separately and thus were excluded from this review (<a href="./references#CD008276-bbs2-0023" title="YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. [MEDLINE: 10639539] ">HOPE HYP 2000</a>; <a href="./references#CD008276-bbs2-0056" title="ErikssonS , OlofssonBO , WesleyPO , for the TEST study group. Atenolol for secondary prevention after stroke. Cerebrovascular Diseases (Basel, Switzerland)1995;5:21‐5. ">TEST 1995</a>; <a href="./references#CD008276-bbs2-0058" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ1998;317:713‐20. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ1998;317:703‐13. ">UKPDS 1998</a>; <a href="./references#CD008276-bbs2-0061" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. A double‐blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents: preliminary results. Archives of Internal Medicine1962;110:230‐5. ">VA‐I 1962</a>; <a href="./references#CD008276-bbs2-0064" title="WolffFW , LindemanRD . Effects of treatment in hypertension. Results of a controlled study. Journal of Chronic Diseases1966;19:227‐40. [MEDLINE: 66114121] ">Wolff 1966</a>; <a href="./references#CD008276-bbs2-0010" title="Anonymous . Control of moderately raised blood pressure: report of a co‐operative randomized controlled trial. British Medical Journal1973;III:434‐6. [MEDLINE: 73241176] ">Anon 1973</a>; <a href="./references#CD008276-bbs2-0011" title="AbernethyJD . The Australian Therapeutic Trial in Mild Hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] Australian National Blood Pressure Management Committee. The Australian Therapeutic Trial in Mild Hypertension. Lancet1980;1:1261‐7. The Management Committee. Treatment of mild hypertension in the elderly. A study initiated and administered by the National Heart Foundation of Australia. Medical Journal of Australia1981;2:398‐402. ">ATTMH 1984</a>; <a href="./references#CD008276-bbs2-0040" title="PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108(9):710‐7. ">PATS 1995</a>). Availability of data for all clinically relevant outcomes from all randomized studies meeting the inclusion criteria in this age group is needed. </p> <p>Three trials combined a reserpine derivative with thiazide as first‐line drug therapy (<a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a>; <a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>). The <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a> trial, which contributed the most weight in this review, added methyldopa if needed to first‐line high‐dose thiazide or beta‐blocker therapy. Therefore, results of this review are mostly applicable to those treatment approaches. </p> <p>Since all seven included studies used high‐dose thiazides, at present we do not have evidence for low‐dose antihypertensive drug therapy as compared to placebo or untreated control in adults aged 18‐ to 59‐years with primary hypertension. Given the findings and conclusions of the first‐line drug review regarding all‐cause mortality and morbidity benefits of using low‐dose thiazide (<a href="./references#CD008276-bbs2-0108" title="WrightJM , MusiniVM . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] ">Wright 2009</a>), we recommend future RCTs compare first‐line low‐dose thiazide with other first‐line classes of antihypertensive drugs in young adults aged 18 to 59 years. </p> </section> <section id="CD008276-sec-0091"> <h3 class="title" id="CD008276-sec-0091">Agreements and disagreements with other studies or reviews</h3> <p>This is the first systematic review of drug therapy in adults aged 18 to 59 years with elevated BP. The ARR in adults aged 18‐ to 59‐years in this review for cardiovascular mortality and morbidity was small (0.9%) with an NNTB of 112 over five years. It is important for clinicians and participants to know the approximate magnitude of benefit in this setting. For people aged 60‐ to 79‐years the absolute reductions over five years were greater, total cardiovascular events, ARR 3.8% with an NNTB 26 over five years (<a href="./references#CD008276-bbs2-0089" title="MusiniVM , TejaniAM , BassettK , WrightJM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000028.pub2] ">Musini 2009</a>). </p> <p>Several guidelines to treat people with hypertension have been published. The eighth revision of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) mainly based their recommendations on evidence from RCTs. However, five out of 10 recommendations are based on expert opinion (<a href="./references#CD008276-bbs2-0079" title="JamesPA , OparilS , CarterBL , CushmanWC , Dennison‐HimmelfarbC , HandlerJ , et al. Evidence‐based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA2014;311(5):507‐20. ">James 2014</a>). </p> <p>They recommended the following:</p> <p> <ul id="CD008276-list-0005"> <li> <p>thiazide‐type diuretics, ACE inhibitors, ARBs and calcium channel blockers as the initial therapy of choice. Although all these drug classes have comparable outcome benefits they concluded that thiazide‐type diuretics are superior to the other three classes in terms of heart failure; </p> </li> <li> <p>specific recommendation in people aged less than 60 years, treatment goal is SBP less than 140 mmHg (expert opinion ‐ grade E evidence); </p> </li> <li> <p>in the general population aged less than 60 years, the target should be DBP less than 90 mmHg and treatment should be initiated above this value (for ages 30 to 59 years, strong recommendation grade A; for ages 18 to 29 years, expert opinion ‐ grade E); </p> </li> <li> <p>in the general population excluding black people (including people with diabetes), initial antihypertensive treatment should include a thiazide‐type diuretic, calcium channel blocker, ACE inhibitor or ARB (general population moderate recommendation ‐ grade B and for black people with diabetes weak recommendation ‐ grade C); </p> </li> <li> <p>beta blockers are no longer considered as an initial therapy option.</p> </li> </ul> </p> <p>The European Society of hypertension (ESH) 2013 guidelines recommend diuretics, beta‐blockers, calcium channel blockers, ACE inhibitors and ARBs are included as viable options for initial hypertension therapy. Goal BP in people with diabetes mellitus is less than 140/85 mmHg. Recommendation for specific age group less than 60 years is SBP/DBP less than 140/90 mmHg (<a href="./references#CD008276-bbs2-0086" title="ManciaG , FagardR , NarkiewiczK , RedónJ , ZanchettiA , BöhmM , et al. Task Force Members, 2013 . 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal2013;34:2159‐219. ">Mancia 2013</a>). </p> <p>The American Society of Hypertension/International Society of Hypertension (ASH/ISH) recommend ACE inhibitors or ARB as initial therapy in non‐black people under 60 years of age; a calcium channel blocker or thiazide diuretic is recommended for black people (<a href="./references#CD008276-bbs2-0105" title="WeberMA , SchiffrinEL , WhiteWB , MannS , LindholmLH , KenersonJG , et al. Clinical practice guidelines for the management of hypertension in the community. A statement by the American Society of Hypertension and the International Society of Hypertension. Journal of Hypertension2014;32(1):3‐15. ">Weber 2014</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008276-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/urn:x-wiley:14651858:media:CD008276:CD008276-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_t/tCD008276-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt='This is a partial study flow diagram and shows search findings from 2008 until 2017. The search done from 1946 to 2008 was identical to the "First line drugs for hypertension" review in which 24 trials met the inclusion criteria of which 17 had to be excluded and only seven studies provided data for quantitative synthesis in 18‐ to 59‐year‐old participants.' data-id="CD008276-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>This is a partial study flow diagram and shows search findings from 2008 until 2017. The search done from 1946 to 2008 was identical to the "First line drugs for hypertension" review in which 24 trials met the inclusion criteria of which 17 had to be excluded and only seven studies provided data for quantitative synthesis in 18‐ to 59‐year‐old participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/full#CD008276-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008276-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/urn:x-wiley:14651858:media:CD008276:CD008276-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_t/tCD008276-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008276-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/full#CD008276-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008276-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/urn:x-wiley:14651858:media:CD008276:CD008276-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_t/tCD008276-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008276-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/full#CD008276-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008276-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/urn:x-wiley:14651858:media:CD008276:CD008276-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_t/tCD008276-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antihypertensive drug therapy versus control, Outcome 1 All‐cause mortality." data-id="CD008276-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Antihypertensive drug therapy versus control, Outcome 1 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/references#CD008276-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008276-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/urn:x-wiley:14651858:media:CD008276:CD008276-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_t/tCD008276-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antihypertensive drug therapy versus control, Outcome 2 Cardiovascular mortality plus morbidity overall." data-id="CD008276-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Antihypertensive drug therapy versus control, Outcome 2 Cardiovascular mortality plus morbidity overall. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/references#CD008276-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008276-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/urn:x-wiley:14651858:media:CD008276:CD008276-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_t/tCD008276-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antihypertensive drug therapy versus control, Outcome 3 Cerebrovascular mortality plus morbidity." data-id="CD008276-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Antihypertensive drug therapy versus control, Outcome 3 Cerebrovascular mortality plus morbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/references#CD008276-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008276-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/urn:x-wiley:14651858:media:CD008276:CD008276-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_t/tCD008276-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antihypertensive drug therapy versus control, Outcome 4 Coronary heart disease mortality plus morbidity." data-id="CD008276-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Antihypertensive drug therapy versus control, Outcome 4 Coronary heart disease mortality plus morbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/references#CD008276-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008276-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/urn:x-wiley:14651858:media:CD008276:CD008276-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_t/tCD008276-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antihypertensive drug therapy versus control, Outcome 5 Withdrawal due to adverse events." data-id="CD008276-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Antihypertensive drug therapy versus control, Outcome 5 Withdrawal due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/references#CD008276-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008276-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/urn:x-wiley:14651858:media:CD008276:CD008276-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_t/tCD008276-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antihypertensive drug therapy versus control, Outcome 6 Decrease in systolic blood pressure." data-id="CD008276-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Antihypertensive drug therapy versus control, Outcome 6 Decrease in systolic blood pressure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/references#CD008276-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008276-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/urn:x-wiley:14651858:media:CD008276:CD008276-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_t/tCD008276-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antihypertensive drug therapy versus control, Outcome 7 Decrease in diastolic blood pressure." data-id="CD008276-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Antihypertensive drug therapy versus control, Outcome 7 Decrease in diastolic blood pressure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/references#CD008276-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/media/CDSR/CD008276/image_n/nCD008276-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008276-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antihypertensive drug therapy compared to control for hypertension in adults aged 18 to 59 years</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antihypertensive drug therapy compared to control for hypertension in adults aged 18 to 59 years</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> antihypertensive drug therapy (mean duration: 5 years)<br/> <b>Comparison:</b> control (placebo or untreated) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antihypertensive drug therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000<br/> (19 to 28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.94<br/> (0.77 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,776<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low <sup>1,2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total cardiovascular mortality + morbidity</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000<br/> (27 to 37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.78<br/> (0.67 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,278<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low <sup>1,3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR 0.9%, NNTB = 112</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cerebrovascular mortality + morbidity</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/> (5 to 9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.46<br/> (0.34 to 0.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,278<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low <sup>1,3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR 0.7%, NNTB 143</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Coronary heart disease mortality + morbidity</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (21 to 31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99<br/> (0.82 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,241<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low <sup>1,3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000<br/> (11 to 93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.82<br/> (1.67 to 13.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1,223<br/> (3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low <sup>1,2,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARI 3.8%, NNTH 27</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Decrease in SBP</b><sup>5</sup> </p> <p>at end of 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean SBP was 0</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 14.98 lower (20.44 lower to 9.52 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,845<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low <sup>1,3,7</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Decrease in DBP</b><sup>6</sup> </p> <p>at end of 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean DBP was 0</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 7.62 lower (10.55 blower to 4.69 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,857<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low <sup>1,3,7</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ARI:</b> absolute risk increase; <b>ARR:</b> absolute risk reduction; <b>CI:</b> confidence interval; <b>DBP:</b> diastolic blood pressure; <b>MD:</b> mean difference; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat to for an additional harmful outcome; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SBP:</b> systolic blood pressure. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Several additional trials met the inclusion criteria but did not report data in the 18‐ to 59‐year‐old subgroup of participants (which are listed under <a href="./references#CD008276-sec-0107" title="">Characteristics of excluded studies</a> table). </p> <p><sup>2</sup>Imprecision due to wide confidence interval. </p> <p><sup>3</sup>High risk of bias due to lack of blinding of physician and participants as well as incomplete outcome data reporting in the MRC‐TMH trial. </p> <p><sup>4</sup>Only 3 out of 7 included trials reported this outcome. The data from <a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a> for this subgroup were not available. High risk of attrition bias and unclear risk of reporting bias of the <a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a> study which contributes 100% weight to the effect size. </p> <p><sup>5</sup>The range of change in SBP in the control group ranged from increase by 1.5 mmHg to decrease from 9 to 14 mmHg. </p> <p><sup>6</sup>The range of decrease in DBP in the control group ranged from 0.6 mmHg to 7 mmHg. </p> <p><sup>7</sup>Significant heterogeneity (I<sup>2</sup> &gt; 95%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antihypertensive drug therapy compared to control for hypertension in adults aged 18 to 59 years</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/full#CD008276-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008276-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics of included studies in all randomized participants aged 18 years or older</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> <p><b> Study design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number of 18‐ to 59‐year‐old participants/total randomized participants (%)</b> </p> <p><b> Characteristics of all randomized participants in each study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mean baseline SBP/DBP </b> </p> <p><b> (mmHg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mean age (range)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Treatment used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcomes reported in 18‐ to 59‐year‐old participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008276-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐89. ">Carter 1970</a> </p> <p>Open label</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49/97 (50.5%);</p> <p>included all hypertensive survivors aged &lt; 80 years of ischaemic type major strokes admitted to Ashford Hospital. </p> <p>Men: 57%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165/101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>(40 to 79 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Untreated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stepped‐up therapy</p> <p>Bendrofluazide (93%), methyldopa and debrisoquine</p> <p>FU 4.0 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008276-bbs2-0002" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a> </p> <p>Double blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252/452 (55.7%).</p> <p>80% of participants had completed stroke in year before randomization; 16% completed stroke + TIA and 4% TIA only. Severe neurological disability in 9.9% of treated group and 5% of control group. </p> <p>Black: 80%</p> <p>Men: 60%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167/100</p> <p>77% of the drug treated and 74% of the placebo treated participants had SBP &lt; 180 mmHg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 years</p> <p>(&lt; 75 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐dose therapy</p> <p>Deserpidine 1 mg + methyclothiazide 10 mg</p> <p>FU 3.0 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality + morbidity</p> <p>Cerebrovascular mortality + morbidity</p> <p>CHD mortality + morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008276-bbs2-0003" title="Anonymous . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub‐studies of the Medical Research Council's trials of treatment of mild hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Anonymous . Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767; CRSREF: 3042232] Anonymous . Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Anonymous . Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986; CRSREF: 3042228] Anonymous . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942; CRSREF: 3042229] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ1985;291(6488):97‐104. [MEDLINE: 85253760; CRSREF: 3042230] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for Mild Hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072; 3042231] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine. Medecine Clinique et Experimentale1987;10(6):616‐20. [MEDLINE: 88151302; CRSREF: 3042233] ">MRC‐TMH 1985</a> </p> <p>Single blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,541/17,354 (83.8%).</p> <p>Men: 52%.</p> <p>Primary prevention participants.</p> <p>Refer to exclusion criteria listed in <a href="./references#CD008276-sec-0106" title="">Characteristics of included studies</a> table. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161/98.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 years</p> <p>(35‐64 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> <p>288/12,375 (0.02%) participants randomly assigned to observation taking no tablets and merged with placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stepped‐up therapy</p> <p>Bendrofluazide 10 mg daily (71% monotherapy), propranolol 80‐240 mg daily (78% monotherapy), methyldopa added if required </p> <p>FU 4.9 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> <p>Cardiovascular mortality + morbidity</p> <p>Cerebrovascular mortality + morbidity</p> <p>CHD mortality + morbidity</p> <p>SBP</p> <p>DBP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008276-bbs2-0004" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The OSLO study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital1982;32:79‐105. [MEDLINE: 83009420] HolmeI , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo data. American Journal of Medicine1986;80(Suppl 2A):306. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] LerenP , HelgelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] ">Oslo 1986</a> </p> <p>Open label</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>785/785 (100%)</p> <p>Men: 100%</p> <p>Primary prevention participants.</p> <p>Refer to exclusion criteria listed in <a href="./references#CD008276-sec-0106" title="">Characteristics of included studies</a> table </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156/97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 years</p> <p>(40‐49 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Untreated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stepped‐up therapy</p> <p>Hydrochlorothiazide (95%), methyldopa and propranolol (26%).</p> <p>At 5‐year follow‐up, 36.7% were on hydrochlorothiazide alone, 26% were on hydrochlorothiazide + propranolol, 20% were on hydrochlorothiazide + methyldopa and 18% participants were on other drugs. </p> <p>FU 5.5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> <p>Cardiovascular mortality + morbidity</p> <p>Cerebrovascular mortality + morbidity</p> <p>CHD mortality + morbidity</p> <p>SBP</p> <p>DBP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008276-bbs2-0005" title="Anonymous . Morbidity and mortality in mild essential hypertension. Circulation Research1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami (FL): Symposia Specialists: In Epidemiology and Control of Hypertension, 1975. US Public Health Service Hospital Cooperative Study Group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circulation Research1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a> </p> <p>Double blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>389/389 (100%)</p> <p>Men: 80%</p> <p>Primary prevention participants.</p> <p>Refer to exclusion criteria listed in <a href="./references#CD008276-sec-0106" title="">Characteristics of included studies</a> table </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147/99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 years</p> <p>(21‐55 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐dose therapy</p> <p>Chlorothiazide 500 mg twice daily + Rauwolfia serpentina 100 mg twice daily</p> <p>FU 7.0 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> <p>Cardiovascular mortality + morbidity</p> <p>Cerebrovascular mortality + morbidity</p> <p>CHD mortality + morbidity</p> <p>SBP</p> <p>DBP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008276-bbs2-0006" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐52. [MEDLINE: 70243223] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation1972;45:991‐1004. ">VA‐II 1970</a> </p> <p>Double blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299/380 (78.7%)</p> <p>Men: 100%</p> <p>Primary prevention participants.</p> <p>Refer to exclusion criteria listed in <a href="./references#CD008276-sec-0106" title="">Characteristics of included studies</a> table </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176/103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 years</p> <p>(range not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stepped‐up therapy</p> <p>First line: hydrochlorothiazide 100 mg + reserpine 0.2 mg</p> <p>Second line: hydralazine 75‐150 mg</p> <p>FU 3.3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality + morbidity</p> <p>Cerebrovascular mortality + morbidity</p> <p>CHD mortality + morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008276-bbs2-0007" title="Anonymous . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. [MEDLINE: 79040327; CRSREF: 3042309] PerryHMJr . Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circulation Research1977;40 Suppl:1180‐7. [MEDLINE: 77160461; CRSREF: 3042310] ">VA‐NHLBI 1977</a> </p> <p>Double blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1012/1012 (100%)</p> <p>Men: 100%</p> <p>Primary prevention participants.</p> <p>Refer to exclusion criteria listed in <a href="./references#CD008276-sec-0106" title="">Characteristics of included studies</a> table </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SBP not reported/93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 years</p> <p>(range 21‐50 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stepped‐up therapy</p> <p>Chlorthalidone 50 mg, 100 mg (53% chlorthalidone alone)</p> <p>Reserpine 0.25 mg</p> <p>FU 1.5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> <p>Cardiovascular mortality + morbidity</p> <p>Cerebrovascular mortality + morbidity</p> <p>CHD mortality + morbidity</p> <p>DBP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total of 7 studies published from 1970 to 1986</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17,327/19,684 (88% of total randomized participants in the 7 studies were 18‐59 years of age) of which only 301/1,7327 (0.02%) participants were secondary prevention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP 147‐176/DBP 99‐103 mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean age 37.5‐45 years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5 RCTs were placebo controlled and 2 RCTS had untreated group as control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mostly high‐dose thiazide and beta‐blockers</b> </p> <p><b>Mean follow‐up 1.5‐7 years.</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5/7 RCTs report on all clinically important outcomes</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CHD: coronary heart disease; DBP: diastolic blood pressure; FU: follow‐up; SBP: systolic blood pressure; TIA: transient ischaemic attack. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics of included studies in all randomized participants aged 18 years or older</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/full#CD008276-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008276-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antihypertensive drug therapy versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16776</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.77, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cardiovascular mortality plus morbidity overall <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.67, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cerebrovascular mortality plus morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.34, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Coronary heart disease mortality plus morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.82, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.82 [1.67, 13.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Decrease in systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14845</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.98 [‐20.44, ‐9.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Decrease in diastolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.62 [‐10.55, ‐4.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antihypertensive drug therapy versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008276.pub2/references#CD008276-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008276.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008276-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008276-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008276-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008276-note-0006">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008276-note-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD008276-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD008276-note-0008">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD008276-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008276-note-0002">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008276-note-0014">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008276\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008276\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008276\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008276\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008276\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008276\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008276\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008276\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008276\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008276\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008276\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008276\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008276\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008276\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008276\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008276\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008276\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008276\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008276.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008276.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008276.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008276.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008276.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725673608"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008276.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725673612"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008276.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e80f47a28f466',t:'MTc0MDcyNTY3My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 